Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
20 Junio 2024 - 7:30AM
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the
“Company”), a specialty pharmaceutical company focused on the
development and commercialization of therapies for the treatment of
neurologic diseases, today announced that Alexandra MacLean, M.D.,
Chief Executive Officer of Avenue Therapeutics, will present at the
H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference.
The presentation will be available to registered attendees for
on-demand viewing on Thursday, June 27, 2024 starting at 7:00 a.m.
ET.
About Avenue TherapeuticsAvenue
Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical
company focused on the development and commercialization of
therapies for the treatment of neurologic diseases. It is currently
developing three assets including AJ201, a first-in-class asset for
spinal and bulbar muscular atrophy, BAER-101, an oral small
molecule selective GABAA α2, α3 receptor positive allosteric
modulator for CNS diseases, and IV tramadol, which is in Phase 3
clinical development for the management of acute post-operative
pain in adults in a medically supervised healthcare setting. Avenue
is headquartered in Miami, FL and was founded by Fortress Biotech,
Inc. (Nasdaq: FBIO). For more information, visit
www.avenuetx.com.
Contact: Jaclyn Jaffe Avenue Therapeutics, Inc.
(781) 652-4500ir@avenuetx.com
Fortress Biotech (NASDAQ:FBIO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Fortress Biotech (NASDAQ:FBIO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
